WO1994005288A1 - Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux - Google Patents

Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux Download PDF

Info

Publication number
WO1994005288A1
WO1994005288A1 PCT/US1993/008192 US9308192W WO9405288A1 WO 1994005288 A1 WO1994005288 A1 WO 1994005288A1 US 9308192 W US9308192 W US 9308192W WO 9405288 A1 WO9405288 A1 WO 9405288A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound according
hydrogen
methyl
nitrogen
methoxy
Prior art date
Application number
PCT/US1993/008192
Other languages
English (en)
Inventor
William R. Kem
John A. Zoltewicz
Edwin M. Meyer
Original Assignee
University Of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida filed Critical University Of Florida
Priority to AT93920438T priority Critical patent/ATE230989T1/de
Priority to EP93920438A priority patent/EP0659078B1/fr
Priority to CA002142610A priority patent/CA2142610C/fr
Priority to AU50979/93A priority patent/AU674541B2/en
Priority to US08/392,763 priority patent/US5741802A/en
Priority to KR1019950700698A priority patent/KR100272614B1/ko
Priority to DE69332641T priority patent/DE69332641T2/de
Priority to JP06507391A priority patent/JP3034953B2/ja
Publication of WO1994005288A1 publication Critical patent/WO1994005288A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

De nouveaux dérivés d'anabaséine et d'anabasine peuvent être utilisés pour stimuler la transmission cholinergique dans le cerveau, et pour traiter des troubles dégénératifs du système nerveux.
PCT/US1993/008192 1992-08-31 1993-08-31 Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux WO1994005288A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT93920438T ATE230989T1 (de) 1992-08-31 1993-08-31 Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
EP93920438A EP0659078B1 (fr) 1992-08-31 1993-08-31 Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux
CA002142610A CA2142610C (fr) 1992-08-31 1993-08-31 Derives d'anabaseine servant au traitement de maladies degeneratives du systeme nerveux
AU50979/93A AU674541B2 (en) 1992-08-31 1993-08-31 Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US08/392,763 US5741802A (en) 1992-08-31 1993-08-31 Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
KR1019950700698A KR100272614B1 (ko) 1992-08-31 1993-08-31 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
DE69332641T DE69332641T2 (de) 1992-08-31 1993-08-31 Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
JP06507391A JP3034953B2 (ja) 1992-08-31 1993-08-31 神経系の変性疾患の治療に有用なアナバセイン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93842792A 1992-08-31 1992-08-31
US938,427 1992-08-31

Publications (1)

Publication Number Publication Date
WO1994005288A1 true WO1994005288A1 (fr) 1994-03-17

Family

ID=25471422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008192 WO1994005288A1 (fr) 1992-08-31 1993-08-31 Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux

Country Status (9)

Country Link
US (1) US5741802A (fr)
EP (1) EP0659078B1 (fr)
JP (1) JP3034953B2 (fr)
KR (1) KR100272614B1 (fr)
AT (1) ATE230989T1 (fr)
AU (1) AU674541B2 (fr)
CA (1) CA2142610C (fr)
DE (1) DE69332641T2 (fr)
WO (1) WO1994005288A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
WO1999010338A2 (fr) * 1997-08-29 1999-03-04 University Of Florida Procedes d'utilisation et compositions de benzylidene-anabasines et cinnamylidene-anabasines
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6316490B1 (en) 1995-11-17 2001-11-13 Merck & Co., Inc. Substituted aryl compounds useful as modulators of acetylcholine receptors
US6346124B1 (en) 1998-08-25 2002-02-12 University Of Florida Autonomous boundary detection system for echocardiographic images
WO2004019943A1 (fr) * 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Derives d'anabaseine utiles pour le traitement de maladies neurodegeneratives
US6708055B2 (en) * 1998-08-25 2004-03-16 University Of Florida Method for automated analysis of apical four-chamber images of the heart
WO2007089626A2 (fr) * 2006-01-26 2007-08-09 Critical Therapeutics, Inc Nouveaux dérivés d'anabaséine, compositions pharmaceutiques et procédés d'utilisation de ceux-ci
EP2300012A2 (fr) * 2008-05-23 2011-03-30 University of South Florida Procédé de traitement d une perte sensorielle des nerfs périphériques à l aide de composés ayant une activité de récepteur nicotinique de l acétylcholine
EP2409703A1 (fr) 2007-08-02 2012-01-25 Targacept, Inc. Traitement avec ligands alpha7 sélectifs
US8476296B2 (en) 2009-01-26 2013-07-02 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US9782404B2 (en) 2008-03-31 2017-10-10 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7639598A (en) 1997-05-29 1998-12-30 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6448276B1 (en) 2000-05-17 2002-09-10 Inspire Pharmaceuticals, Inc. Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
JP2005522457A (ja) * 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
RU2391341C2 (ru) 2002-09-25 2010-06-10 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
ES2293086T3 (es) * 2002-12-06 2008-03-16 The Feinstein Institute For Medical Research Inhibicion de la inflamacion usando agonistas colinergicos de union al receptor alfa 7.
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
NZ550534A (en) 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2007530586A (ja) * 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
ATE489132T1 (de) 2004-12-27 2010-12-15 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs
EP1891036A4 (fr) 2005-06-07 2010-08-04 Univ Florida Ligands sélectifs du récepteur nicotinique alpha 7
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2009029614A1 (fr) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Dispositifs et procédés permettant d'inhiber l'activation de granulocytes par stimulation neurale
US9211409B2 (en) * 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2011022467A2 (fr) * 2009-08-21 2011-02-24 University Of Florida Research Foundation, Inc. Formulations à libération contrôlée de composés anabaséine et utilisations de celles-ci
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP3636314B1 (fr) 2009-12-23 2021-09-08 Setpoint Medical Corporation Dispositifs et systèmes de stimulation neuronale pour le traitement de l'inflammation chronique
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
AR082138A1 (es) * 2010-07-12 2012-11-14 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127756A1 (fr) 2016-01-20 2017-07-27 Setpoint Medical Corporation Commande de stimulation vagale
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (fr) 2016-01-20 2017-07-27 Setpoint Medical Corporation Microstimulateurs implantables et systèmes de recharge par induction
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
WO2019036470A1 (fr) 2017-08-14 2019-02-21 Setpoint Medical Corporation Test de dépistage pour stimulation du nerf vague
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2021249608A2 (fr) * 2020-06-09 2021-12-16 Elkazaz Mohamed Fadly Abd El Ghany Nouveau médicament pour la modulation immunitaire et le traitement d'une inflammation chronique ou d'une hyper-inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4195645A (en) * 1978-03-13 1980-04-01 Celanese Corporation Tobacco-substitute smoking material
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275625A (en) * 1966-09-27 Derivatives of
US3426130A (en) * 1960-12-19 1969-02-04 Squibb & Sons Inc Compositions containing a benzothiadiazinesulfonamide 1,1-dioxide
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
ES2153357T3 (es) * 1991-03-01 2001-03-01 Univ Florida Uso de analogos nicotinicos para el tratamiento de enfermedades degenerativas del sistema nervioso.
CA2142610C (fr) * 1992-08-31 2003-09-16 William R. Kem Derives d'anabaseine servant au traitement de maladies degeneratives du systeme nerveux
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4195645A (en) * 1978-03-13 1980-04-01 Celanese Corporation Tobacco-substitute smoking material
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Hackh's Chemical Dictionary", published 1983 by McGraw-Hill Book Co., see page 642. *
Bioorganic Chem., Vol. 18, issued 1990, ZOLTEWICZ, "Hydrolysis of Cholinergic Anabaseine and Anabaseine -N-Me", see page 403. *
Bull. Chem. Society of Japan, Volume 57, issued 1984, NOMURA Y. et al., "The Relation of 5-Benzylidine-2,3,4,5-Tetra Hyeropyridine with some Nucleophiles", see page 1271. *
CHEMICAL ABSTRACTS, Volume 113, No. 1, issued July 2, 1990, GALLULO V. et al., "Cyclization of -Halo Nitriles with Organo-Lithiums", see Abstr. No. 6111k, Org. Prep. Procedures 21(3), pages 297-301 (Eng). *
CHEMICAL ABSTRACTS, Volume 54, No. 8, issued 25 April 1960, FUJISAWA T. et al., "Extension of Bichler Napieralski Reaction", see Abstr. No. 7702e, Tetrahedron 7, pages 185-8. *
CHEMICAL ABSTRACTS, Volume 59, No. 10, issued 11 November 1963, SEIYAKU T. et al., "Novel Hetero Cyclic Compounds", see Abstr. No. 11447h. *
Il. Farmaco. Science, Volume XL, issued 1985, TRAPANI T. et al., "Esi Ed Attivita Autimicrobia in Vitro di Derivati Sostitutiti di Fenilpiperidine E Fenilipiperazine", see pages 673-674. *
J. of Organic Chemistry, Vol. 28, issued 1963, PARCELL, R.F. et al., "The Preparation of Tetrahydro Pyridines from Enamines and Imines", see page 3469. *
TU, "Handbook of Natural Toxins", published 1988 by Marcel Dekker Inc. (N.Y.), see page 358. *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6316490B1 (en) 1995-11-17 2001-11-13 Merck & Co., Inc. Substituted aryl compounds useful as modulators of acetylcholine receptors
WO1999010338A3 (fr) * 1997-08-29 1999-05-14 Univ Florida Procedes d'utilisation et compositions de benzylidene-anabasines et cinnamylidene-anabasines
WO1999010338A2 (fr) * 1997-08-29 1999-03-04 University Of Florida Procedes d'utilisation et compositions de benzylidene-anabasines et cinnamylidene-anabasines
US6346124B1 (en) 1998-08-25 2002-02-12 University Of Florida Autonomous boundary detection system for echocardiographic images
US6708055B2 (en) * 1998-08-25 2004-03-16 University Of Florida Method for automated analysis of apical four-chamber images of the heart
US6716175B2 (en) 1998-08-25 2004-04-06 University Of Florida Autonomous boundary detection system for echocardiographic images
EP2298759A1 (fr) * 2002-08-30 2011-03-23 Memory Pharmaceuticals Corporation Dérivés d'anabaseine utiles pour le traitement de maladies neurodégénératives
WO2004019943A1 (fr) * 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Derives d'anabaseine utiles pour le traitement de maladies neurodegeneratives
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
US7994199B2 (en) 2002-08-30 2011-08-09 Memory Pharmaceuticals Corporation Heterocyclic compounds, methods for the preparation thereof, and uses thereof
EP2305664A1 (fr) * 2002-08-30 2011-04-06 Memory Pharmaceuticals Corporation Dérivés d'anabaseine utiles pour le traitement de maladies neurodégéneratives
US7700630B2 (en) 2002-08-30 2010-04-20 Memory Pharmaceuticals Corporation Heterocyclic compounds, methods for the preparation thereof, and uses thereof
EP2298758A1 (fr) * 2002-08-30 2011-03-23 Memory Pharmaceuticals Corporation Dérivés d'anabaseine utiles pour le traitement de maladies neurodégénératives
WO2007089626A2 (fr) * 2006-01-26 2007-08-09 Critical Therapeutics, Inc Nouveaux dérivés d'anabaséine, compositions pharmaceutiques et procédés d'utilisation de ceux-ci
US7662965B2 (en) 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
WO2007089626A3 (fr) * 2006-01-26 2008-01-03 Critical Therapeutics Inc Nouveaux dérivés d'anabaséine, compositions pharmaceutiques et procédés d'utilisation de ceux-ci
US8008499B2 (en) 2006-01-26 2011-08-30 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and methods of use thereof
EP2409703A1 (fr) 2007-08-02 2012-01-25 Targacept, Inc. Traitement avec ligands alpha7 sélectifs
EP2484363A1 (fr) 2007-08-02 2012-08-08 Targacept, Inc. (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide
US9782404B2 (en) 2008-03-31 2017-10-10 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2300012A2 (fr) * 2008-05-23 2011-03-30 University of South Florida Procédé de traitement d une perte sensorielle des nerfs périphériques à l aide de composés ayant une activité de récepteur nicotinique de l acétylcholine
EP2300012A4 (fr) * 2008-05-23 2011-07-06 Univ South Florida Procédé de traitement d une perte sensorielle des nerfs périphériques à l aide de composés ayant une activité de récepteur nicotinique de l acétylcholine
US8476296B2 (en) 2009-01-26 2013-07-02 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US8901151B2 (en) 2009-01-26 2014-12-02 Targacept, Inc. Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US9173876B2 (en) 2009-01-26 2015-11-03 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide

Also Published As

Publication number Publication date
EP0659078A4 (fr) 1996-04-24
KR100272614B1 (ko) 2000-11-15
AU674541B2 (en) 1997-01-02
CA2142610C (fr) 2003-09-16
CA2142610A1 (fr) 1994-03-17
JPH08509458A (ja) 1996-10-08
KR950702829A (ko) 1995-08-23
US5741802A (en) 1998-04-21
DE69332641D1 (de) 2003-02-20
AU5097993A (en) 1994-03-29
DE69332641T2 (de) 2003-11-27
EP0659078A1 (fr) 1995-06-28
ATE230989T1 (de) 2003-02-15
JP3034953B2 (ja) 2000-04-17
EP0659078B1 (fr) 2003-01-15

Similar Documents

Publication Publication Date Title
US5741802A (en) Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
AU652434B2 (en) Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
CA2111461C (fr) Derives de la 3-aminopiperidine et composes heterocycliques azotes apparentes
US5977144A (en) Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
EP1758860A1 (fr) 3-pyridyl-benzocycloalkylmethylamines saturees et insaturees destinees au traitement de douleurs, de depressions et d'etats d'angoisse
WO2000064884A1 (fr) Derives de piperidyle-imidazole, preparations dans lesquelles ils entrent et utilisations therapeutiques de ces dernieres
US6353008B1 (en) Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
DE69731658T2 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
JPH11228411A (ja) 掻痒症の治療法
KR100364340B1 (ko) 이미다졸리디논유도체,이의산부가염및노인성치매치료제
US6465453B1 (en) Azepine derivatives having effects on serotonin related systems
JPH08208603A (ja) メラトニン剤としての３−アルコキシベンジルピペリジン誘導体
JP2001504847A (ja) 重抑鬱障害の治療のためのｎｋ−１受容体拮抗薬の使用
US6664274B1 (en) Piperidine derivatives as serotonine reuptake inhibitors
CA2386092A1 (fr) Derives de piperidine
US5286733A (en) Substituted 3-piperidinealkanoates and alkanones and compositions and method of use thereof
EP1572653A1 (fr) Heteroarylcycloalkymethyl amines saturees et insaturees en tant qu'antidepresseurs
DD212516A5 (de) Verfahren zur herstellung von cyclischen dihydropyridylimidatestern

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2142610

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019950700698

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1993920438

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993920438

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08392763

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1993920438

Country of ref document: EP